Literature DB >> 15914203

Nucleotide excision repair- and p53-deficient mouse models in cancer research.

Esther M Hoogervorst1, Harry van Steeg, Annemieke de Vries.   

Abstract

Cancer is caused by the loss of controlled cell growth due to mutational (in)activation of critical genes known to be involved in cell cycle regulation. Three main mechanisms are known to be involved in the prevention of cells from becoming cancerous; DNA repair and cell cycle control, important to remove DNA damage before it will be fixed into mutations and apoptosis, resulting in the elimination of cells containing severe DNA damage. Several human syndromes are known to have (partially) deficiencies in these pathways, and are therefore highly cancer prone. Examples are xeroderma pigmentosum (XP) caused by an inborn defect in the nucleotide excision repair (NER) pathway and the Li-Fraumeni syndrome, which is the result of a germ line mutation in the p53 gene. XP patients develop skin cancer on sun exposed areas at a relatively early age, whereas Li-Fraumeni patients spontaneously develop a wide variety of early onset tumors, including sarcomas, leukemia's and mammary gland carcinomas. Several mouse models have been generated to mimic these human syndromes, providing us information about the role of these particular gene defects in the tumorigenesis process. In this review, spontaneous phenotypes of mice deficient for nucleotide excision repair and/or the p53 gene will be described, together with their responses upon exposure to either chemical carcinogens or radiation. Furthermore, possible applications of these and newly generated mouse models for cancer will be given.

Entities:  

Mesh:

Year:  2005        PMID: 15914203     DOI: 10.1016/j.mrfmmm.2005.01.018

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  8 in total

1.  Base excision repair activities differ in human lung cancer cells and corresponding normal controls.

Authors:  Bensu Karahalil; Vilhelm A Bohr; Nadja C De Souza-Pinto
Journal:  Anticancer Res       Date:  2010-12       Impact factor: 2.480

2.  Bio-evaluation of the role of chitosan and curcumin nanoparticles in ameliorating genotoxicity and inflammatory responses in rats' gastric tissue followed hydroxyapatite nanoparticles' oral uptake.

Authors:  Israa F Mosa; Haitham H Abd; Abdelsalam Abuzreda; Nadhom Assaf; Amenh B Yousif
Journal:  Toxicol Res (Camb)       Date:  2020-08-03       Impact factor: 3.524

3.  PCNA is recruited to irradiated chromatin in late S-phase and is most pronounced in G2 phase of the cell cycle.

Authors:  Eva Bártová; Jana Suchánková; Soňa Legartová; Barbora Malyšková; Matúš Hornáček; Magdalena Skalníková; Martin Mašata; Ivan Raška; Stanislav Kozubek
Journal:  Protoplasma       Date:  2017-01-20       Impact factor: 3.356

4.  Nuclear dynamics of PCNA in DNA replication and repair.

Authors:  Jeroen Essers; Arjan F Theil; Céline Baldeyron; Wiggert A van Cappellen; Adriaan B Houtsmuller; Roland Kanaar; Wim Vermeulen
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272

Review 5.  Do mutator mutations fuel tumorigenesis?

Authors:  Edward J Fox; Marc J Prindle; Lawrence A Loeb
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

6.  Impaired expression of NER gene network in sporadic solid tumors.

Authors:  Mauro A A Castro; José C M Mombach; Rita M C de Almeida; José C F Moreira
Journal:  Nucleic Acids Res       Date:  2007-03-01       Impact factor: 16.971

7.  Diverse hematological malignancies including hodgkin-like lymphomas develop in chimeric MHC class II transgenic mice.

Authors:  Silke H Raffegerst; Gabriele Hoelzlwimmer; Sandra Kunder; Josef Mysliwietz; Leticia Quintanilla-Martinez; Dolores J Schendel
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

8.  Erianin inhibits human cervical cancer cell through regulation of tumor protein p53 via the extracellular signal-regulated kinase signaling pathway.

Authors:  Mengting Li; Yulin He; Cheng Peng; Xiaofang Xie; Guanying Hu
Journal:  Oncol Lett       Date:  2018-08-03       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.